Strategic partnerships There is a track record of partnerships and distribution (Japan Lifeline collaboration, US presence) suggesting appetite for channel partnerships and co-development opportunities to expand market reach in electrophysiology and transseptal devices.

Acquisition tailwinds Baylis Medical sold its cardiology business to Boston Scientific in 2021, indicating potential for ongoing technology transfer, licensing, or integration opportunities with large incumbents seeking to augment their portfolio in cardiovascular devices.

Clinical adoption Strong clinical deployment with VersaCross Large Access Solution and ExpanSure across Canada and initial LAAC use signals demand for advanced access and delivery systems; potential upsell to hospitals upgrading EP and LAAC workflows.

Emerging markets Global offices and multi-year presence in cardiology and spine devices point to opportunities in regions where adoption of advanced EPcatheter and transseptal systems is growing, aided by partnerships and local clinical training.

Technology stack Adoption of modern analytics and design tools (Power BI, Tableau, SOLIDWORKS, SAP, Salesforce) aligns with selling into mid-market hospital networks that value data-driven outcomes and integrated CRM and ERP for procurement efficiency.